Detalhe da pesquisa
1.
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Invest New Drugs
; 37(2): 345-351, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30610588